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Abstract  
Background and aims.  
Micro-and macrovascular complications of diabetes, such as retinopathy and nephropathy progress 
over time and may be associated with cognitive decline. In this paper we aimed at gaining further 
insight into the association between cognitive function and retinopathy in type 2 diabetes. 
Methods and results. 
Observational 8-year prospective study of 498 outpatients. Demographic and clinical variables were 
monitored, along with retinopathy, depression, anxiety and cognitive function. Baseline fundus 
photographs were available in 477 patients, 240 with no retinopathy, 110 with mild, and 127 with 
moderate/more severe retinopathy. Of the first two groups, 279 patients were re-evaluated after 8 
years, of whom 181 still had no/mild retinopathy and 98 had progressed to more severe stages. On 
multivariate analysis, retinopathy progression was associated with being insulin treated (p=0.036), 
and worse cognitive function (p=0.025) at baseline.  
Conclusions. 
Cognitive function may be an independent predictor of retinopathy progression.  
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Introduction. 
Most clinical studies showed a direct correlation between glycemic control over time and incidence 
and progression of Diabetic Retinopathy (DR) in type 2 diabetes (1). Type 2 Diabetes Mellitus 
(T2DM) is predominantly managed during daily life by the persons with the disease and/or their 
care providers. Since adequate treatment of diabetes depends on patients’ adherence to demanding 
lifestyle and medication regimens, cognitive factors may play a critical role in its management.  
We reported previously on prevalence and progression over 8 years (2) of depression, anxiety and 
cognitive function in a cohort of patients with T2DM. In this subanalysis, we investigated the 
possible clinical and psycho-cognitive predictors of DR progression in the same cohort. 
 
Materials and Methods. 
Design  
Four-hundred and ninety-eight outpatients with type 2 diabetes, 249 on insulin treatment (IT) and 
249 on other agents (NIT) were enrolled in an observational prospective study. Their detailed 
baseline clinical and psycho-cognitive data were reported previously (2). Patients were mostly 
Caucasian aged 40-80, routinely followed in urban diabetes clinics. Exclusion criteria were history 
of psychiatric illnesses in the patients or their families, presence of cancer, renal replacement 
therapy or other life-limiting chronic conditions.  
Eight years later, the patients were invited to a follow-up visit, to which they gave their informed 
consent in accordance with the Declaration of Helsinki principles. Details of those lost to follow-up 
or dead were reported in detail elsewhere (2). Data on age, gender, schooling, occupation, family 
status, smoking status, self monitoring of blood glucose, family history and duration of diabetes, 
body weight, HbA1c (HPLC, according to IFCC), fasting blood glucose (glucose-oxidase), blood 
pressure, serum creatinine, total and HDL cholesterol, triglyceride were collected.  
Fundus examination was by 2-field, 45° digital colour photography, using a Canon CR6-45NM 
fundus camera (Canon Inc, Ochigiken, Japan). Retinopathy was classified as absent if 
corresponding to ETDRS standard 10, mild if doubtful or ETDRS =20, and moderate or more 
severe if ETDRS ≥35 (3). Grading of the worse eye was considered to assign severity. 
Cognitive Assessment 
Cognitive performance was evaluated by Mini Mental State Examination, (MMSE) (4), 
administered as a semi-structured interview. Median reference scores change with age, ranging 
from 29, for individuals 18 to 24 years of age, to 25 for those aged 80 years and older, and years 
spent in formal education, ranging from 29 for individuals with ≥9 years of schooling, 26 for those 
with 5-8 years, to 22 for those with 0-4 years of schooling. Depression and anxiety were assessed 
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by the Zung Self-rating scales (5). All tools had been translated into Italian and revalidated. If the 
patients had literacy problems, the questionnaires were completed with the help of a health operator. 
Statistical Analysis. 
Descriptive data are shown as absolute frequencies of the different modalities for categorical data 
and as mean ± standard deviation for continuous variables. T-test for continuous variables and chi-
square or Fisher exact test for qualitative variables were carried out to compare data at baseline of 
possible predictors of DR after 8 years for patients with no or mild retinopathy at 8 years and 
patients who developed moderate-severe retinopathy. In order to adjust for the relative effect of 
each predictor of the development of severe DR, retinopathy after 8 years (moderate-severe vs no-
mild) was inserted as the dependent variable in a logistic regression model, where clinical and 
psycho-cognitive data at baseline, i.e. age, gender, glucose lowering treatment (IT vs NIT), HbA1c, 
retinopathy (mild vs none), depression, anxiety and MMSE scores, were originally inserted as 
independent variables. After testing for interaction between HbA1c and retinopathy we decided to 
insert in the model the two composite variables representing HbA1c with no retinopathy and the 
other with HbA1c and mild retinopathy. Depression and anxiety were intercorrelated with MMSE 
but didn’t show any significant relation with retinopathy after 8 years follow up, therefore were 
dropped out of the model. The final model is shown in Table 1. 
Significance level was set at α=0.05. All analyses were performed with Stata 13. 
Results 
Out of 477 patients for whom fundus evaluation was available at baseline, 240 (160 IT and 80 NIT) 
had no DR and 110 (48 NIT and 62 IT) had mild non proliferative DR. Another 127 (24 NIT and 
103 IT) already had moderate or more severe DR at baseline and therefore were not considered in 
this analysis. Of the first two groups, 279 (80%) patients could be re-evaluated at 8 years, of whom 
181 had no or mild DR and 98 had progressed to moderate/more severe DR.   
The 98 patients who progressed to moderate/more severe DR were older (66.4 ± 6.9 vs 66.3 ± 8.2; 
p=0.032), more likely to be on insulin treatment (46 NIT/52 IT vs 119 NIT/62 IT; p=0.003), 
practised more frequent self-monitoring of blood glucose (p=0.024), had higher HbA1c (8.30% ± 
1.2 vs 7.87% ± 1.03 or 67.19 ± 13.16 vs 62.60 ± 14.26 mmol/mol; p=0.009) and lower MMSE 
scores (24.24 ± 3.47 vs 25.37 ± 3.76; p=0.017) at baseline. On multivariate analysis (Table 1), 
being on insulin treatment (OR 1.91, 95%CI 1.04;3.50, p=0.036) and having higher HbA1c in 
patients with mild DR at baseline (OR 1.45, 1.13;1.85, p=0.003) were associated with progression 
to moderate or more severe DR, whereas male gender (OR 0.49, 0.27;0.90, p=0.021) and a higher 
MMSE score (indicative of better cognitive ability) (OR 0.90 per score point; 0.83;0.99, p=0.025) 
were protective.  
Discussion. 
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In this longitudinal observation, DR progression over 8 years was more likely to occur in older 
insulin treated individuals with worse metabolic control and lower cognitive performance at 
baseline, suggesting that, in patients with long-lasting diabetes, microvascular damage may 
simultaneously affect the retina and the brain, both parts of the central nervous system with 
common anatomical origins and structure.  
Previous research on the links between retinopathy and cognitive impairment is mostly in the 
direction of the former preceding or predicting the latter (6), whereas our results suggest that the 
relationship may be bi-directional. An association between advanced diabetic retinopathy and risk 
of cognitive decline or overt dementia was reported (7,8), and cerebral microbleeds and retinal 
microvascular signs were related to evidence of vascular cognitive impairment (9). Others found 
that the risk of mild cognitive impairment may be more than doubled if diabetic retinopathy is 
present (10). A recent systematic review reported an association between cognitive impairment and 
diabetic retinopathy, although only in older males or patients with established macrovascular 
disease (11). Indeed, both retinopathy and cognitive impairment share a number of risk factors with 
large vessel disease, such as hypertension and dyslipidemia (12) and, although in this paper MMSE 
scores predicted later progression of diabetic retinopathy independently of hypertension and serum 
cholesterol or triglyceride, a contribution of these factors cannot be ruled out. It should be pointed 
out that, although we followed them up for 8 years (2), we did not detect severe cognitive 
impairment in our patients. However, a worsening trend did occur and lower MMSE scores at 
baseline, even though within age- and schooling-adjusted reference limits, predicted progression of 
diabetic retinopathy. This study includes a large outpatient population that was carefully followed 
for a long period of time and used standardized procedures to monitor clinical and psycho-cognitive 
variables. Limitations are that it was not designed to detect predictors for long term complications, 
although retinopathy, renal function and cardiovascular risk factors were carefully monitored as part 
of routine care. In addition, data on adherence to diet and therapy were not collected systematically. 
Poor adherence may be associated with, among others, polypharmacy (13) and impaired quality of 
life (14) in type 2 diabetes, both present in most of our patients, and be a risk factor for vascular 
complications.  
In conclusion, end-organ complications of type 2 diabetes may affect different sections of the 
central nervous system and a test as simple as the MMSE, even when not signalling overtly 
impaired cognitive function, may hold independent predictive value for the progression of diabetic 
retinopathy. 
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Table 1. Multivariate analysis of the effect of predictors of progression to moderate/more 
severe DR 
 
Data at baseline Odds Ratio CI  95% p-value 
Age  1.03 0.99; 1.07 0.194 
Male gender 0.49 0.27; 0.90 0.021 
Insulin treatment vs not 1.91 1.04; 3.50 0.036 
HbA1c in pts with no 
retinopathy at basaline* 
1.21 0.95; 1.53 0.122 
HbA1c in pts with mild 
retinopathy at basaline* 
1.45 1.13; 1.85 0.003 
MMSE score   0.90 0.83; 0.99 0.025 
 
*we tested for interaction between HbA1c and retinopathy at baseline 
 
 
 
 
 
